Oncology - Panome Bio

Oncometabolomics for Biomarker
Discovery and Disease Diagnosis

Oncometabolomics is a field of study that focuses on the analysis of the metabolic changes that occur in cancer cells. It aims to identify new biomarkers and therapeutic targets for cancer. With Panome Bio’s Next-Generation Metabolomics platform, you can discover new biomarkers, evaluate therapeutic targets and get valuable insights to the phenotype of disease.

Oncometabolomics for Biomarker Discovery and Disease Diagnosis

Gain-of-function mutations in is-citrate dehydrogenase 1 (IDH1) occur in multiple types of cancer. These mutations
result in the enzyme producing the oncometabolite, 2-hydroxygulutarate, which leads to the formation of cancer.

Case Study

A metabolomics study found that the oncometabolite 2-hydroxyglutarate (2-HG) is produced at high levels in glioma cells harboring gain of function mutation in isocitrate dehydrogenase (IDH), which is an enzyme in the citric acid cycle.

Inhibiting the enzyme that produces 2-HG reduce the growth of glioma cells, indicating that targeting 2-HG production may be an effective therapeutic strategy for glioma.

Visit our resources section for more information on Panome Bio’s applications in oncology!


Skip to content